New center will focus on antimicrobial resistance, TB treatments
The London School of Hygiene and Tropical Medicine (LSHTM) announced today that it is partnering with Johnson & Johnson (J&J) to launch a center focused on research into antimicrobial resistance and tuberculosis (TB).
According to an LSHTM press release, the J&J Center for Global Health Discovery will “advance the critical, early-stage discovery and exploratory science needed to develop potentially lifesaving innovations to address diseases that disproportionately impact the world’s poorest and most vulnerable people.”
The center will focus specifically on research into next-generation drug regimens needed to treat all forms of TB.
“By bringing together the excellent science of institutions like LSHTM with Johnson and Johnson’s expertise in translational research, I believe we can not only bridge but fill the gaps in innovation needed to tackle the world’s urgent health issues,” said Anil Koul, PhD, vice president and head for Global Health Discovery and Partnerships at J&J, and a professor of translational research at LSHTM.
The center will be part of a larger and decentralized scientific network being developed by J&J to drive pharmaceutical research and development in parts of the world where the need is greatest.
Jul 9 LSHTM press release
Real-world, in vitro data show promise for cefiderocol against gram-negs
Japanese drug maker Shionogi & Co. is presenting what it calls key new data on the antibiotic cefiderocol at the annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which begins today.
In a company press release, Shionogi, of Osaka, said an overview of susceptibility and clinical outcomes found that the overall clinical response was positive in 141 patients who received the novel cephalosporin antibiotic in a global compassionate use program. The patients had infections caused by gram-negative pathogens resistant to all alternative antibiotics, mainly Pseudomonas aeruginosa (50%) and Acinetobacter baumannii complex (24%).
Initial data from the cefiderocol Early Access Programme for patients with gram-negative infections showed that of 237 patients treated with the antibiotic, 40.5% had carbapenem-resistant A baumannii infections, 32.9% had carbapenem-resistant P aeruginosa infections, and 37.1% were also co-infected with COVID-19.
“Shionogi is excited to share these real-world data at ECCMID, providing initial evidence that cefiderocol is addressing the high unmet need for new antimicrobials effective against important resistant pathogens, such as carbapenem-resistant Acinetobacter or Pseudomonas,” said Mark Hill, MBBS, Shionogi’s global head of market access.
The company also cited studies showing that cefiderocol demonstrated extensive in vitro activity against carbapenem-resistant gram-negative isolates collected from Europe and the United States as part of the SENTRY Antimicrobial Surveillance Program.
Cefiderocol, sold under the brand name Fetroja, was approved for treating complicated urinary tract infections by the Food and Drug Administration in 2019, then for treatment of hospital-acquired and ventilator-associated pneumonia the following year. It’s one of two antibiotics that England’s National Health Service has selected for purchase under its pilot subscription-style payment model, which aims to pay developers of innovative antibiotics annually for access to their products, rather than reimbursing them based on the quantity of antibiotics sold.
Jul 8 Shionogi press release